NAD+ Suppositories is one of the major delivery formats for NAD+ precursors. Rectal NAD+ administration. Bypasses first-pass hepatic metabolism. Niche format with limited brand availability.
This guide covers the mechanism, the practical pros and cons, who this format is best for, and an exact dosing protocol.
NAD+ (nicotinamide adenine dinucleotide) is a redox coenzyme present in every cell. It powers mitochondrial ATP production via the electron-transport chain, fuels DNA-repair enzymes (PARPs), and is the obligatory substrate for sirtuins (SIRT1–SIRT7) — the enzyme family that controls gene expression, inflammation, and cellular survival.
NAD+ levels fall by 50% or more between ages 30 and 60. That decline is now considered a leading mechanistic explanation for age-related metabolic dysfunction, mitochondrial fatigue, accumulation of senescent cells, and the loss of muscle, skin, and cognitive resilience seen in aging.
NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are the two NAD+ precursors with the strongest human data. Both raise NAD+ via the salvage pathway: NR is phosphorylated by NRK1/NRK2 to form NMN, then converted to NAD+; NMN is dephosphorylated to NR for cellular uptake or — per Imai's lab — taken up directly through the Slc12a8 transporter in mouse small intestine. NADH is the reduced electron-carrying form. Niacinamide (nicotinamide) and niacin (nicotinic acid) are cheaper but raise NAD+ less efficiently, and high-dose nicotinamide (>1 g/day) inhibits sirtuins.
CD38, an NAD+-degrading enzyme, rises with age. Inhibitors of CD38 — apigenin, quercetin, luteolin — preserve the NAD+ you make. Methylation cofactors (TMG, B12, folate) become depleted with high-dose precursor use because the body methylates excess nicotinamide for excretion.
Mechanism / pharmacokinetics. Rectal NAD+ administration. Bypasses first-pass hepatic metabolism. Niche format with limited brand availability.
Best suited for. Users with severe GI absorption issues. Niche use case.
Trade-offs vs other formats. Cost, convenience, peak plasma profile, and clinical evidence base differ across formats. Standard oral capsule has the most clinical support; sublingual and IV achieve higher peak plasma at higher cost or oversight requirements.
Exact protocol. Per product instructions. Typically 200–500 mg per suppository, 1× daily.
Stack with. TMG (methylation), apigenin (CD38 inhibition), methylated B-complex. These complement any NMN format.
When to switch formats. If your current format produces no subjective benefit at 8–12 weeks, consider switching (capsule → sublingual, or oral → IV cycle) to vary pharmacokinetics.
Is NAD+ Suppositories better than capsule NMN?
Better is goal-dependent. NAD+ Suppositories offers convenience; standard capsules have the deepest clinical evidence base. Choose based on your priorities.
Can I switch between formats?
Yes. Many users alternate (e.g., capsule daily, IV quarterly). Different pharmacokinetics may produce different subjective effects.
What's the cost difference?
NAD+ Suppositories is typically comparable to standard capsules.